PALO ALTO, Calif., April 2, 2020 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company
developing novel therapeutics to treat chronic, high-prevalence
retinal diseases, today announced the appointment of Charles Bancroft to its board of directors.
Charlie recently retired from a successful career at Bristol
Myers Squibb (BMS) where he held a number of leadership roles in
commercial, strategy and finance. Beginning his career at BMS in
1984, he held numerous roles of increasing responsibility. He
served as Chief Financial Officer from 2010 to 2019 and was
appointed Executive Vice President, Head of Integration and
Strategy & Business Development in 2019. He received his
bachelor's degree in accounting from Drexel
University and his M.B.A. in finance from Temple University.
Charlie served as a member of the board of Colgate-Palmolive
Company from 2017 to March 2020. He
was appointed to GlaxoSmithKline's board of directors as a
Non-Executive Director in March
2020.
"Charlie joins our board as Kodiak accelerates its research and
development activities and begins pre-commercial planning for
KSI-301," said Victor Perlroth,
M.D., Chief Executive Officer of Kodiak Sciences. "We welcome
Charlie's leadership and expertise as we scale our organization and
build manufacturing and commercial capabilities in support of our
global pipeline of retinal medicines."
"I am thrilled to join Kodiak's board of directors. Kodiak
continues to demonstrate impressive progress with KSI-301 and its
pipeline of product candidates built on its ABC Platform," said
Charles Bancroft. "I look forward to
working with the Kodiak team on their journey to develop and
commercialize the next generation of retinal medicines."
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a clinical stage biopharmaceutical
company developing novel therapeutics to treat chronic,
high-prevalence retinal diseases. Founded in 2009, we are focused
on bringing new science to the design and manufacture of next
generation retinal medicines to prevent and treat the leading
causes of blindness globally. Our ABC Platform™ uses molecular
engineering to merge the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration, a leading cause of blindness in elderly
patients, and diabetic eye diseases, a leading cause of blindness
in working-age patients. Kodiak has leveraged its ABC Platform to
build a pipeline of product candidates in various stages of
development including KSI-501, our bispecific anti-IL-6/VEGF
biopolymer conjugate for the treatment of neovascular retinal
diseases with an inflammatory component, and we are expanding our
early research pipeline to include ABC Platform based triplet
inhibitors for multifactorial retinal diseases such as dry AMD and
glaucoma. Kodiak is based in Palo Alto, CA. For more
information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC
Platform™ and the Kodiak logo are registered trademarks or
trademarks of Kodiak Sciences Inc. in various global
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-appoints-charles-bancroft-to-board-of-directors-301033770.html
SOURCE Kodiak Sciences Inc.